GSK Paxil DTC Pullback Decreases Downside From Black Box Requirement
This article was originally published in The Pink Sheet Daily
Executive Summary
GlaxoSmithKline does not foresee a significant impact from the antidepressant "black box" class warning requirement since it has already pulled back Paxil direct-to-consumer ads